Denali Therapeutics Inc.
COMPOUNDS, COMPOSITIONS AND METHODS

Last updated:

Abstract:

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

Status:
Application
Type:

Utility

Filling date:

8 Aug 2018

Issue date:

20 May 2021